Definition of Gemtuzumab. Meaning of Gemtuzumab. Synonyms of Gemtuzumab

Here you will find one or more explanations in English for the word Gemtuzumab. Also in the bottom left of the page several parts of wikipedia pages related to the word Gemtuzumab and, of course, Gemtuzumab synonyms and on the right images related to the word Gemtuzumab.

Definition of Gemtuzumab

No result for Gemtuzumab. Showing similar results...

Meaning of Gemtuzumab from wikipedia

- Gemtuzumab ozogamicin, sold under the brand name Mylotarg®, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute...
- proteins, its expression is known to be tied to TREM2. CD33 is the target of gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories),...
- Gemtuzumab Ozogamicin: Reintroduction Based on Favorable Risk:Benefit Profile". ADCReview. September 2, 2017. Retrieved August 14, 2024. "Gemtuzumab Ozogamicin...
- release from the differentiating promyelocytes. The monoclonal antibody, gemtuzumab ozogamicin, has been used successfully as a treatment for APL, although...
- FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab...
- bullet" due to their targeting properties. In 2001 Pfizer/Wyeth's drug Gemtuzumab ozogamicin (trade name: Mylotarg) was approved based on a study with a...
- traditional systemic approaches. The first approved drug of this type was gemtuzumab ozogamicin (Mylotarg), released by Wyeth (now Pfizer). The drug was approved...
- dimethylhydrazide. It includes the same linker, called "AcBut", and toxin, as gemtuzumab ozogamicin, which arose from the same collaboration. The linker is a carbonyl-containing...
- they are linked to a cytotoxic agent from the class of calicheamicins. Gemtuzumab ozogamicin Inotuzumab ozogamicin "マイロターグ点滴静注用5mg インタビューフォーム" [Myrotarg...
- Union Liver toxicity. Gatifloxacin 2006 US Increased risk of dysglycemia. Gemtuzumab ozogamicin (Mylotarg) 2010 US No improvement in clinical benefit; risk...